Mitsubishi Tanabe Obtains Additional Indication For Bisoprolol
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma has obtained an additional indication of chronic heart failure for Maintate (bisoprolol) in Japan